NDAINHALATIONAEROSOL, METERED
Approved
Apr 2016
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1
Data completeness
7/8 — Comprehensive
BEVESPI AEROSPHERE (glycopyrrolate and formoterol fumarate) by AstraZeneca is fumarate. Approved for copd, asthma, chronic obstructive pulmonary disease. First approved in 2016.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BEVESPI AEROSPHERE is a dual-mechanism inhaled maintenance bronchodilator combining glycopyrrolate (long-acting anticholinergic) and formoterol fumarate (long-acting beta-2 agonist) for COPD and asthma. It works by blocking M3 muscarinic receptors in airway smooth muscle while simultaneously stimulating beta-2 adrenergic receptors to produce sustained bronchodilation. The combination addresses complementary physiological pathways to optimize airway opening.
$67MPart D
PeakStable
4.7 years to LOEBEVESPI is in peak commercial phase with strong Medicare utilization (118K+ claims), supporting a mature field sales and medical affairs infrastructure at AstraZeneca.
Mechanism of Action
fumarate. The mechanism of action described below for the individual components applies to BEVESPI AEROSPHERE. These drugs represent two different classes of medications (an anticholinergic, and a long-acting selective beta 2 -adrenoceptor agonist) that have different effects on clinical physiology…
Worked on BEVESPI AEROSPHERE at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.